BUZZ-ImmunityBio on positive early data for cancer treatment regimen
Reuters
Aug 26
BUZZ-ImmunityBio on positive early data for cancer treatment regimen
** Shares of drugmaker ImmunityBio IBRX.O rise 4.4% to $2.35
** Co says early data shows its experimental cancer treatment regimen shows promise when tested in five patients
** Co was testing its treatment regimen in patients with recurrent glioblastoma or brain tumor
** Co says all five patients achieved 100% disease control with the treatment regimen which also includes its drug Anktiva which is approved to treat a type of bladder cancer
** Including session's move, stock down 12.1% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.